There are three federally approved medications to treat chronic opioid addiction in the United States: methadone, buprenorphine, and Vivitrol/naltrexone. All three medications can be used as part of treatment for opioid addiction delivered through the federally certified and licensed Opioid Treatment Programs (OTPs). The AATOD Board of Directors believes that it is important for all OTPs to consider using all federally approved medications to treat chronic opioid addiction as we work in greater cooperation with Drug Courts, correctional facilities, and probation and parole offices. It is also important to use all federally approved medications, as noted above, as we prepare for the full implementation of Health Care Reform.
The AATOD Board of Directors asked the Medications Committee to develop the attached Vivitrol/Naltrexone Guidelines in OTPs. Dr. Brian McCarroll is the principal author of these guidelines and worked with his associates on the Medications Committee, as Chaired by Dr. George Stavros. The entire AATOD Board of Directors had the opportunity to review these guidelines in detail and have approved them for release to our field.
These guidelines have also been reviewed by our associates in the professional medical communities in addition to a number of State Opioid Treatment Authorities and physicians who work in our field.
It is the Board’s collective hope that these guidelines will encourage the use of these medications in OTPs as part of treatment and relapse prevention.